The elderly population is increasing worldwide. Despite a major decrease in deaths from coronary heart disease (CHD), this malady remains the major cause of death in elderly men and women. In this paper, we review the role of dyslipidemia as a major known risk factor in the pathogenesis of CHD, age-related changes in lipoprotein metabolism, and differences in changes in lipids that occur in men and women during aging. Next we provide an overview of the available studies and recommendations from ATP III. Finally, we comment on the screening and management, cost and side effects of therapy as it applies to an aging population.
Adult Treatment Panel III (2002) Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults . Circulation106: 3143-3421.
2.
Anum, E. and Adera, T. ( 2004) Hypercholesterolemia and coronary heart disease in the elderly: a meta-analysis. Ann Epidemiol14: 705-721.
3.
Benfante, R. and Reed, D. ( 1990) Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly? JAMA263: 393-396.
4.
Berge, K.G. and Canner, P.L. ( 1991) Coronary drug project: experience with niacin. Eur J Clin Pharmacol40: S49-S51.
5.
Christensen, K., Doblhammer, G., Rau, R. and Vaupel, J.W.(2009) Ageing populations: the challenges ahead. Lancet374: 1196-1208.
6.
Downs, J.R., Clearfield, M., Weis, S., Whitney, S., Shapiro, D.R., Beere, P.A. et al. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: result of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study . JAMA279: 1615-1622.
7.
Cholesterol Treatment Trialists’ (CTT) Collaborators ( 2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet366: 1267-1278.
8.
Ericsson, S., Eriksson, M., Vitols, S., Einarsson, K., Berglund, L., Angelin, B. et al. (1991) Influence of age on the metabolism of plasma low density lipoproteins in healthy males. J Clin Invest87: 591-596.
9.
Ferrara, A. and Barrett-Connor, S.J. ( 1997) Total LDL and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994. Circulation96: 37-43.
10.
Frost, P.H., Davis, B.R., Burlando, A.J., Curb, J.D., Guthrie, G.P., Isaacsohn, J.L. et al. (1996) Serum lipids and incidence of coronary heart disease: findings from the Systolic Hypertension in the Elderly Program (SHEP) . Circulation94: 2381-2388.
11.
Fruchart, J.-C., Sacks, F.M., Hermans, M.P., Assmann, G., Brown, W.V., Ceska, W. et al. (2008) The Residual Risk Reduction Initiative: a call to action to reduce residual risk in dyslipidaemic patients. Diab Vasc Dis Res5: 319-335.
12.
Grundy, S.M., Pasternak, R., Greenland, P., Smith, S. and Fuster, V. ( 1999) Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation34: 1348-1359.
13.
Heart Protection Study Collaborative Group ( 2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial. Lancet360: 7-22.
14.
Heart Protection StudyCollaborative Group(2009) Statin cost-effectiveness in the united states for people at different vascular risk levels. Circulation: Cardiovasc Quality Outcomes2: 65-72.
15.
Houmard, J.A., Weidner, M.D., Dolan, P.L., Leggett-Frazier, N., Gavigan, K.E., Hickey, M.S. et al. (1995) Skeletal muscle GLUT4 protein concentration and aging in humans. Diabetes44: 555-560.
16.
Iversen, A., Jensen, J.S., Scharling, H. and Schnohr, P.(2009) Hypercholesterolaemia and risk of coronary heart disease in the elderly: impact of age: the Copenhagen City Heart Study. Eur J Intern Med20: 139-144.
17.
Kreisberg, R.A. and Kasim, S. ( 1987) Cholesterol metabolism and aging. Am J Med82: 54-60.
18.
LaRosa, J.C., Applegate, W., Crouse, J.R., Hunninghake, D.B., Grimm, R., Knopp, R. et al. (1994) Cholesterol lowering in the elderly. Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study. Arch Intern Med154: 529-539.
19.
Lau, W.C., Waskell, L.A., Watkins, P.B., Neer, C.J., Horowitz, K. and Hopp, A.S. ( 2003) Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation107: 32-37.
20.
Launay-Vacher, V., Izzedine, H. and Deray, G. ( 2005) Statins’ dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patient. Intern J Cardiology101: 9-17.
21.
Le Couteur, D.G., Cogger, V.C., McCuskey, R.S., DeCabo, R., Smedsrod, B. and Sorensen, K.K. ( 2007) Age-related changes in the liver sinusoidal endothelium: a mechanism for dyslipidemia. Ann NY Acad Sci1114: 79-87.
22.
Lindblad, U., Langer, R.D., Wingard, D.L., Thomas, R.G. and Barrett-Connor, E.L. ( 2001) Metabolic syndrome and ischemic heart disease in elderly men and women. Am J Epidemiol153: 481-489.
23.
Maher, V.W., Brown, B.G., Marcovina, S.M., Hillger, L.A., Zhao, X.-Q., Albers, J.J. et al. (1995) Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA274: 1771-1774.
24.
Malenka, D.J. and Baron, J.A. ( 1988) Cholesterol and coronary heart disease: the importance of patient-specific attributable risk. Arch Intern Med148: 2247-2252.
25.
Manolio, T.A., Pearson, T.A., Wenger, N.K., Barrett-Connor, E., Payne, G.H. and Harlan, W.R. ( 1992) Cholesterol and heart disease in older persons and women: review of an NHLBI Workshop. Ann Epidemiol2: 161-176.
26.
Merz, T. and Fuller, S.H. ( 2007) Elevated serum transaminase levels resulting from concomitant use of rosuvastatin and amiodarone. Am J Health-Syst Pharm64: 1818-1821.
27.
Miettinen, T.A., Pyorala, K., Olsson, A.G., Musliner, T.A., Cook, T.J., Faergeman, O. et al. (1997) Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation96: 4211-4218.
28.
Neil, H.A., DeMicco, D.A., Luo, D., Betterridge, D.J., Colhoun, H.M., Durrington, P.N. et al. (2006) Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care29: 2378-2384.
29.
Sacks, F.M., Pfeffer, M.A., Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G. et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med335: 1001-1009.
30.
Santinga, J.T., Rosman, H.S., Rubenfire, M., Maciejko, J.J., Kobylak, L., McGovern, M.E. et al. (1994) Efficacy and safety of pravastatin n the long-term treatment of elderly patients with hypercholesterolemia. Am J Med96: 509-515.
31.
Sattar, N., Preiss, D., Murray, H.M., Welsh, P., Buckley, B.M., de Craen, A.J.M. et al. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet in press .
32.
Sawabe, M., Tanaka, N., Nakahara, K., Hamamatsu, A., Chida, K., Arai, T. et al. (2009) High lipoprotein (a) level promotes both coronary atherosclerosis and myocardial infarction: a path analysis using a large number of autopsy cases. Heart95: 1997-2002.
33.
Sever, P.S., Dahlof, B., Poulter, N.R., Wedel, H., Beevers, G., Caulfield, M. et al. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet361: 1149-1158.
34.
Shepherd, J., Blauw, G.J., Murphy, M.B., Bollen, E.L., Buckley, B.M., Cobbe, S.M. et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet360: 1623-1630.
35.
Shepherd, J., Cobbe, S.M., Ford, I., Isles, C.G., Lorimer, A.R., MacFarlane, P.W. et al. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med333: 1301-1307.
36.
Sorrentino, S.A., Besler, C., Rohrer, L., Meyer, M., Heinrich, K., Bahlmann, F.H. et al. (2010) Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation121: 110-122.
37.
Sukhija, R., Prayaga, S., Marashdeh, M., Bursac, Z., Kakar, P., Bansal, D. et al. (2009) Effect of statin on fasting plasma glucose in diabetic and nondiabetic patients. J Invest Med57: 495-499.
38.
Taylor, A.J., Villines, T.C., Stanek, E.J., Devine, P.J., Griffen, L., Miller, M. et al. (2009) Extended-release or ezetimibe and carotid intima-media thickness . N Engl J Med361: 2113-2122.
39.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med339: 1349-1357.
40.
Tziomalos, K., Athyros, V.G., Wierzbicki, A.S. and Mikhailidis, D.P.(2009) Lipoprotein a: where are we now? Current Opin Cardiol24: 351-357.
41.
Wagstaff, L.R., Mitton, M.W., Arvik, B.M. and Doraiswamy, P.M. ( 2003) Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy23: 871-880.
